A Study of Steady-state Rifampin on the Single-dose of Erdafitinib Tablets in Healthy Adult Participants
Status:
Suspended
Trial end date:
2022-03-07
Target enrollment:
Participant gender:
Summary
The main purpose of this study is to evaluate the effect of multiple doses of rifampin (a
strong inducer of CYP3A4 and a moderate inducer of CYP2C9) on the pharmacokinetics of a
single oral dose of erdafitinib in healthy adult participants.
Phase:
Phase 1
Details
Lead Sponsor:
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.